[Home] [Headlines] [Latest Articles] [Latest Comments] [Post] [Sign-in] [Mail] [Setup] [Help]
Status: Not Logged In; Sign In
|
Health See other Health Articles Title: “Alzheimer’s Disease is Now Completely Treatable” Teaser What's the 25-cent prion-targeting stock that Agora's Breakthrough Technology Alert is saying will have a "miracle announcement" on February 14? II Comments: goldtharhills One miracle drug is not going to solve what is a complex disease involving a number of bio challenges…more than 30, according to Dr. Dale Bredesen who has had amazing success in California over 30 years of research, demonstrating in documented clinical trials that his approach is helping people stabilize, partially recover or be cured. His “Bredesen Protocol” involves a myriad of suspects in Alzheimers, including heavy metal toxicity. His work is well documented as googling will reveal. My wife’s ex-husband lived with us for a year in 2016-7. He was 54 when he came down with early Alz. We did the full protocol with him, under an integrative doctor’s supervision. Unfortunately it did not reverse his symptoms. Now at 57, he is fairly advanced though lately has stabilized. We still give him some of the supplements. he is now living near us with his daughter and boyfriend, and has full time care, which we didn’t as it was too expensive. Our research made it clear to us why one drug is never going to solve the Alz. equation: it involves many variables and even then, at least for now, it can be hit or miss. There’s also the factor of “will to live” which we’re not sure was present in our case, as this is a man who routinely told his daughters when they were under 10 that he didn’t want to get very old because it was so physically unattractive and unpleasant what happens to the bodies of old people. You begin to get the idea what kind of person this is. We began to wonder just how negative the psychological aspect of his illness is. bigger Disclaimer: I’m the largest shareholder in this company. I have no clue what the February 14th headline is. The way to think about PMN310 is a drug similar to Aducanumab that binds to the Toxic Oligomers but doesn’t bind the fibril (plaque) which is the driver of the Aria-E side effect of Adu. Aducanumab binds to both the toxic oligomer and the plaque. PMN310 doesn’t bind to the monomer. I’ll leave it at that given the size of my position. I had no clue this article was coming out yesterday and I have never talk to Blanco. I don’t know the guy.. I’m cited on the landing page because I wrote a blog post about it a long time ago. Michael schubrrw3212 Mr Blanco may have his signals crossed. Another company with links to a potential Alzheimer’s drug has news due in litigation that’s set for Feb 14th. Kannalife and Isodiol International investor Marvin Washington is suing the US DEA for practicing medicine without a license. The lawsuit, Washington v Sessions, is up for hearing on a motion by AG Jeff Sessions to dismiss it so that DEA does not have to admit or deny the charges. Mr Washington bought the rights to US Patent 6,630,507 on a brain protection drug invented by 3 NIMH scientists, then hit a snag when trying to arrange FDA clinical trials. DEA would not let them make the raw material needed to make and test the drug. They researched where DEA got the authority to second-guess the FDA, found that there was a temporary authority that should have expired 44 years ago, and sued. Mr Sessions does not want to lose his powers in the case and will obviously appeal an unfavorable ruling. Mr Washington does not want to lose his patent rights in the case, and likely will also appeal an unfavorable ruling. I predict this case will end up in the Supreme Court sometime next year. Meanwhile, the fact that the DEA blocked development of an Alzheimer’s drug because it’s too dumb to know the damage it’s doing, will likely move a lot of stocks on Feb 14th, particularly the ones that took a hit 2 weeks ago when Jeff Sessions last made news on cannabis. Can anyone say, “You’re fired”? Mark T I figured out who it was yesterday Travis, and when I saw it was pre-stage my immediate enthusiasm waned. However, if anyone is gonna find the cure for AD and ALS it IS this guy. He has been at it some 35 years and has won the prestigious Jonas Salk lifetime achievement lifetime award in this field. This Dr Neil Cashman and his newly public co. have proven that big pharma has been wrong and selling false hope for years to the victims of these diseases, his patented methods already have better results than any meds out there now, and I for one am gonna buy&hold a bunch at 25 cents a share…even if nothing happens til 2021. Breakthrough Technology Alert ProMIS Neurosciences (PMN.TO ARFXF) S. Sloan Alzheimer’s is one of the most devastating diseases known to plague mankind. Better odds of cure with stem cell therapy, particularly with mesenchymal cells. Check out Dr. Neil Riordan in Panama and Texas. Early work is very promising . Dr. KSS MD PhD My intent in commenting on ProMIS is not to make it look risible (I don’t question its sincerity in its approach and its belief in the authenticity of its work) but simply to caution investors and safeguard against capital losses. I see several issues about its approach that are not necessarily problems unique to ProMIS: (1) the amyloid hypothesis has serious deficits. Science cannot even answer why amyloid is elaborated, though we have made contentions in early commentaries about its origin. (2) Two major theories of the ailment have gained considerable momentum: these would be the dampened synaptic transmission hypothesis and the RAGE receptor-driven neuroinflammation hypothesis. The Candida torulopsis hypothesis is strong but needs further testing by a clinical antimicrobial trial. (3) people keep forgetting that monoclonal antibodies are possibly the worst reagents to be using to go after Alzheimers. They are being used as stoichiometric binding agents in pursuit of amyloid occupancy. But does this make sense? Satisfying establishment of the mere extent to which mAb’s, among the largest molecules the body sees, can cross the blood brain barrier is lacking. People also forget that IgG is complement-fixing, and thus evokes strong secondary inflammatory responses; ProMIS I admit is using an IgG4 that may have abated complement-inducing activities though I’d need to see data to be sure. But even if complement is not activated, there is the issue of Fc receptor binding after antigen engagement, and Fc receptors abound….on macrophages, other immune cells, even on platelets. Thereby CNS inflammation is further stoked. An anticalin would be vastly more ideal in pursuit of finding an anti-amyloid reagent, though I doubt any solution lies in the amyloid approach to things. (4) no disease being pursued by biotech has a greater gulf between in vitro and in vivo investigative mechanisms; a cell culture model of AD that is genuinely relevant on all axes is impossible, and no definitive animal model exists. We cannot be invasive (ie, brain biopsies) in assessment of the histopathology, which radically alters itself upon death. A true solution may await further development of miniature CNS agglomerations ex vivo attained by 3-D bioprinting or by signalling of stem cells , along with tactics to replicate presence of an immune system. (5) $CWBR has a mitochondrially elaborated peptide that reverses amyloid induced neurotoxicity and neuron paucity. The mechanism is only partly known but tends to undermine the amyloid hypothesis. Rather, I regard the best theory of AD is that it represents a local CNS diabetes with mitochondriopathy and failed constitutive mitochondrial peptide elaboration. Support of this model is amassing rapidly. I predict CohBar is on track to have a serious remedy for AD more so than any company in biotech, and this is based on non-privileged information albeit info the company has yet to present in a wide manner. Above all else I certainly wish Michael Bigger good fortune in his investing pursuits and respect his considerable intelligence. I think it’s fair to assert here that Bigger may be aware of information that is not public and that being a sizable shareholder may have given him access, via an NDA, to data we cannot know that supported his decision to invest. And if so, I hope he wins and wins massively. His integrity, good attitude and kindness are unsurpassed and his cerebral horsepower formidable. rbblum I believe that it is Biogen that remains on the ‘fast track’ for its Alzheimers drug . . . It should be only a relatively short amount of time yet to determine whether it will be marketable or fall to the wayside. Current test results look rather promising. Gambini I read an article on researchers at MIT who engineered mice with AH of the brain and by aiming light at certain intervals (optogenetics) directly at each neuron , thereby eliminating the AH effects. The scientists then duplicated the effects by having the mice stare at this same light delivered at the same intervals. Human trials are expected in the very near future. Different approach than chemicals. I’m hopeful; lost a cousin to AH last year who developed it one yr after retirement at 62 yrs . His wife was the caregiver for 11 years; needless to say, they both suffered. Yes, indeed, it will be miraculous if/when there is a cure. bakermre The only authoritative/reliable source on treatment published as/of late 2017 is Dale E. Bredesen, M.D. book: The End of Alzheimer’s, publ. by Avery, Penguin Random House, 375 Hudson St. N.Y., NY 10014. ISBN 978073516204. 36 specific factors that together are the principle causes of the disease are clinically identified and specific treatments for each defined. Hundreds of patients suffering from early to mid-stage Alzheimer’s have had recoveries recorded, documented by a widely respected peer group. Also see David Perlmutter, M.D. and Sara Gottfried, M.D. NY Times best selling authors on this affliction. Any other claim that fails to include Bredesen’s protocols are doomed to failure. No single drug or treatment can correct 36 factors that add up to progressive cognitive decline and eventual Alzheimer’s. Post Comment Private Reply Ignore Thread
|
||
|
[Home]
[Headlines]
[Latest Articles]
[Latest Comments]
[Post]
[Sign-in]
[Mail]
[Setup]
[Help]
|
||